Published in Vaccine Weekly, May 10th, 2006
DOR is designing BT-VACC to be administered by the mucosal route, which offers significant advantages to the end user in terms of increased safety, lack of pain from injections, and ability to induce protective antibodies in the lung and intestines. These types of antibodies are associated with inactivation of botulinum toxins before they enter the body. These results are the first ever report of a combination of botulinum vaccine...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.